Overall survival · people with advanced gastric cancer
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Overall survival ‐ FOLFIRINOX · advanced pancreatic cancer
Various types of chemotherapy probably leads to lower overall survival ‐ FOLFIRINOX compared with gemcitabine (moderate certainty).
1 finding from 1 review
Overall survival · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival · patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in overall survival (low certainty).
1 finding from 1 review
Overall survival · patients with small‐volume primary oropharyngeal carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (1‐year · people with pancreatic and periampullary adenocarcinoma
It is very uncertain whether extended changes overall survival (1‐year compared with standard lymph node resection (very low certainty).
1 finding from 1 review